22945-10-4

Upstream product

• 82140-93-0 C₁₉H₁₈O₂ 

Downstream Products

• 22944-96-3 3,3-dimethyl-6-(toluene-4-sulfonyl)-2,4-dioxa-6-aza-bicyclo[3.2.0]heptan-7-one 
• 82140-88-3 1-(2,2-Dimethyl-[1,3]dioxol-4-yl)-cyclohexanol 
• 61845-71-4 trans 1,2,3,4-bis(isopropylidenedioxy)-cyclobutane 
• 108805-95-4 exo-6,7-isopropylidenedioxy-1-methoxytricyclo<3.3.0.0^2.8>-oct-3-en 
• 108805-95-4 endo-6,7-isopropylidenedioxy-1-methoxytricyclo<3.3.0.0^2.8>-oct-3-en 
• 108805-96-5 exo-7,8-isopropylidenedioxy-1-methoxybicyclo<4.2.0>octa-2,4-diene 
• 108805-96-5 endo-7,8-isopropylidenedioxy-1-methoxybicyclo<4.2.0>octa-2,4-diene 
• 289891-12-9 2,2-dimethyl-7-phenyl-7,7a-dihydro-3aH-[1,3]dioxolo[4,5-b]pyran-5-carboxylic acid methyl ester 
• 84035-66-5 5-(Hydroxy-phenyl-methyl)-2,2-dimethyl-[1,3]dioxole-4-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Modified Nucleosides for Rna Interference

The present invention relates to the use of modified nucleotides and single or double stranded oligonucleotides having at least one of said modified nucleotides for performing RNA interference. The modified nucleotides are selected from 6-membered ring containing nucleotides such as hexitol, altritol, O-substituted or O-alkylated altritol, cyclohexenyl, ribo-cyclohexenyl and O-substituted or O-alkylated ribo-cyclohexenyl nucleotides. The present invention also relates to novel modified nucleosides or nucleotides and to the use of the novel modified nucleosides and nucleotides in single or double stranded oligonucleotides for RNA interference, antisense therapy or other applications.

Synthesis and conformational analysis of a ribo-type cyclohexenyl nucleoside

A straightforward approach to a novel class of ribo-type cyclohexenyl nucleosides is described. An electron-demand Diels-Alder reaction forms the key-step of the chosen synthetic pathway. Although the difference is small, conformational analysis using NMR shows that this nucleoside analogue adopts preferentially an 2H3 conformation (S-type), while the "deoxy" cyclohexenyl analogue has a preference for a C3′ endo conformation (N-type). Analyses of the conformational equilibrium reveal that, in the given experimental conditions, the difference between adenosine and its cyclohexenyl congener resides in their different ΔG values; furthermore, in adenosine, the conformational preference is of enthalpic origin, whereas in the cyclohexenyl congener, the conformational preference is of entropic origin.